Your browser doesn't support javascript.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Agathangelidis, Andreas; Chatzidimitriou, Anastasia; Gemenetzi, Katerina; Giudicelli, Veronique; Karypidou, Maria; Plevova, Karla; Davis, Zadie; Yan, Xiao-Jie; Jeromin, Sabine; Schneider, Christof; Pedersen, Lone Bredo; Tschumper, Renee C; Sutton, Lesley-Ann; Baliakas, Panagiotis; Scarfò, Lydia; van Gastel, Ellen J; Armand, Marine; Tausch, Eugen; Biderman, Bella; Baer, Constance; Bagnara, Davide; Navarro, Alba; Langlois de Septenville, Anne; Guido, Valentina; Mitterbauer-Hohendanner, Gerlinde; Dimovski, Aleksandar; Brieghel, Christian; Lawless, Sarah; Meggendorfer, Manja; Brazdilova, Kamila; Ritgen, Matthias; Facco, Monica; Tresoldi, Cristina; Visentin, Andrea; Patriarca, Andrea; Catherwood, Mark; Bonello, Lisa; Sudarikov, Andrey; Vanura, Katrina; Roumelioti, Maria; Skuhrova Francova, Hana; Moysiadis, Theodoros; Veronese, Silvio; Giannopoulos, Krzysztof; Mansouri, Larry; Karan-Djurasevic, Teodora; Sandaltzopoulos, Raphael; Bödör, Csaba; Fais, Franco; Kater, Arnon P.
  • Agathangelidis A; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
  • Chatzidimitriou A; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
  • Gemenetzi K; Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
  • Giudicelli V; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
  • Karypidou M; Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
  • Plevova K; International ImMunoGeneTics Information System (IMGT), Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Unité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France.
  • Davis Z; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
  • Yan XJ; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
  • Jeromin S; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Schneider C; Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.
  • Pedersen LB; The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY.
  • Tschumper RC; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Sutton LA; University Hospital Medical Center, Ulm, Germany.
  • Baliakas P; Deparment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Scarfò L; Department of Immunology, Mayo Clinic, Rochester, MN.
  • van Gastel EJ; Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
  • Armand M; Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Tausch E; Strategic Research Program on CLL, B-Cell Neoplasia Unit, Division of Experimental Oncology, Università Vita-Salute San Raffaele/Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
  • Biderman B; Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center (UMC), Rotterdam, The Netherlands.
  • Baer C; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne Université, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.
  • Bagnara D; Department of Internal Medicine III, Ulm University, Ulm, Germany.
  • Navarro A; National Research Center for Hematology, Moscow, Russia.
  • Langlois de Septenville A; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Guido V; Department of Experimental Medicine, University of Genoa, Genoa, Italy.
  • Mitterbauer-Hohendanner G; Centro de Investigacion Biomedica en Red en Oncologia (CIBERONC), Madrid, Spain.
  • Dimovski A; Institut d'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain.
  • Brieghel C; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne Université, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.
  • Lawless S; Molecular Pathology Unit, Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
  • Meggendorfer M; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Brazdilova K; Faculty of Pharmacy, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Northern Macedonia.
  • Ritgen M; Deparment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Facco M; Clinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.
  • Tresoldi C; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Visentin A; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
  • Patriarca A; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Catherwood M; Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Bonello L; Hematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Sudarikov A; Veneto Institute of Molecular Medicine, Padua, Italy.
  • Vanura K; Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Roumelioti M; Hematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Skuhrova Francova H; Veneto Institute of Molecular Medicine, Padua, Italy.
  • Moysiadis T; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont-Ospedale Maggiore della Carità, Novara, Italy.
  • Veronese S; Clinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.
  • Giannopoulos K; General Anatomopathology and Molecular Oncogenetics, Azienda Ospedaliero Universitaria (AOU), City of Health and Science of Turin, Turin, Italy.
  • Mansouri L; National Research Center for Hematology, Moscow, Russia.
  • Karan-Djurasevic T; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Sandaltzopoulos R; First Department of Propaedeutic Medicine, University of Athens, Athens, Greece.
  • Bödör C; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
  • Fais F; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
  • Kater AP; Molecular Pathology Unit, Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
Blood ; 137(10): 1365-1376, 2021 03 11.
Article in English | MEDLINE | ID: covidwho-1127679
ABSTRACT
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed "satellites," were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin Variable Region / Leukemia, Lymphocytic, Chronic, B-Cell / Immunoglobulin Heavy Chains Type of study: Cohort study / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Blood Year: 2021 Document Type: Article Affiliation country: Blood.2020007039

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin Variable Region / Leukemia, Lymphocytic, Chronic, B-Cell / Immunoglobulin Heavy Chains Type of study: Cohort study / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Blood Year: 2021 Document Type: Article Affiliation country: Blood.2020007039